Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2

Breast and ovarian cancer (BC/OC) predisposition has been attributed to a number of high‐ and moderate to low‐penetrance susceptibility genes. With the advent of next generation sequencing (NGS) simultaneous testing of these genes has become feasible. In this monocentric study, we report results of panel‐based screening of 14 BC/OC susceptibility genes (BRCA1, BRCA2, RAD51C, RAD51D, CHEK2, PALB2, ATM, NBN, CDH1, TP53, MLH1, MSH2, MSH6 and PMS2) in a group of 581 consecutive individuals from a German population with BC and/or OC fulfilling diagnostic criteria for BRCA1 and BRCA2 testing including 179 with a triple‐negative tumor. Altogether we identified 106 deleterious mutations in 105 (18%) patients in 10 different genes, including seven different exon deletions. Of these 106 mutations, 16 (15%) were novel and only six were found in BRCA1/2. To further characterize mutations located in or nearby splicing consensus sites we performed RT‐PCR analysis which allowed confirmation of pathogenicity in 7 of 9 mutations analyzed. In PALB2, we identified a deleterious variant in six cases. All but one were associated with early onset BC and a positive family history indicating that penetrance for PALB2 mutations is comparable to BRCA2. Overall, extended testing beyond BRCA1/2 identified a deleterious mutation in further 6% of patients. As a downside, 89 variants of uncertain significance were identified highlighting the need for comprehensive variant databases. In conclusion, panel testing yields more accurate information on genetic cancer risk than assessing BRCA1/2 alone and wide‐spread testing will help improve penetrance assessment of variants in these risk genes.

[1]  H Tesch,et al.  Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. , 2015, Geburtshilfe und Frauenheilkunde.

[2]  Rochelle L. Garcia,et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[3]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[4]  P. Fasching,et al.  Breast Cancer Update 2014 - Focus on the Patient and the Tumour. , 2015, Geburtshilfe und Frauenheilkunde.

[5]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[6]  A. Zharkikh,et al.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.

[7]  B. Bonanni,et al.  Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome , 2014, Genes, chromosomes & cancer.

[8]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[9]  B. Boman,et al.  Identification of seven novel germline mutations in the human E‐cadherin (CDH1) Gene , 2007, Human mutation.

[10]  S. Knudsen,et al.  Prediction of human mRNA donor and acceptor sites from the DNA sequence. , 1991, Journal of molecular biology.

[11]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[12]  E. Velasco,et al.  Functional Classification of BRCA2 DNA Variants by Splicing Assays in a Large Minigene with 9 Exons , 2015, Human mutation.

[13]  T. Walsh,et al.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.

[14]  T. Walsh,et al.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. , 2011, Cancer research.

[15]  Shunsuke Kato,et al.  Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods , 2006, Nucleic acids research.

[16]  Lihong Liu,et al.  The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. , 2013, DNA and cell biology.

[17]  Peter G. Korning,et al.  Splice Site Prediction in Arabidopsis Thaliana Pre-mRNA by Combining Local and Global Sequence Information , 1996 .

[18]  Tanja Fehm,et al.  Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer , 2016, Journal of Medical Genetics.

[19]  Christophe Béroud,et al.  UMD‐Predictor: A High‐Throughput Sequencing Compliant System for Pathogenicity Prediction of any Human cDNA Substitution , 2016, Human mutation.

[20]  Alfons Meindl,et al.  Analysis of 30 Putative BRCA1 Splicing Mutations in Hereditary Breast and Ovarian Cancer Families Identifies Exonic Splice Site Mutations That Escape In Silico Prediction , 2012, PloS one.

[21]  Kenneth Offit,et al.  Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention , 2014, Science.

[22]  B. Ravčuková,et al.  No major effect of the CDH1 c.2440‐6C>G mutation on splicing detected in last exon‐specific splicing minigene assay , 2014, Genes, chromosomes & cancer.

[23]  Man Li,et al.  Functional variants in NBS1 and cancer risk: evidence from a meta-analysis of 60 publications with 111 individual studies. , 2013, Mutagenesis.

[24]  R. Kreienberg,et al.  First Revision of the German S3 Guideline ‘Diagnosis, Therapy, and Follow-Up of Breast Cancer’ , 2008, Breast Care.

[25]  P. Ang,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[26]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[27]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[28]  Jan Hauke,et al.  Genetik des familiären Brust- und Eierstockkrebses: Paneldiagnostik – Möglichkeiten und Grenzen , 2015, medizinische genetik.

[29]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[30]  K. Lu,et al.  Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention , 2013, Familial Cancer.

[31]  S. Kean.  Breast cancer. The 'other' breast cancer genes. , 2014, Science.

[32]  David Haussler,et al.  Improved splice site detection in Genie , 1997, RECOMB '97.

[33]  Douglas F. Easton,et al.  Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics , 2003, Human Genetics.

[34]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.